Soleno Therapeutics Holds Annual Stockholders Meeting

Soleno Therapeutics ( (SLNO) ) just unveiled an announcement.

On June 5, 2025, Soleno Therapeutics held its Annual Meeting of Stockholders, where approximately 94.7% of the outstanding shares were represented. The stockholders elected two Class II directors and ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SLNO) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.

Spark’s Take on SLNO Stock

According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.

Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.

To see Spark’s full report on SLNO stock, click here.

More about Soleno Therapeutics

Soleno Therapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Average Trading Volume: 1,335,437

Technical Sentiment Signal: Buy

Current Market Cap: $3.88B

Find detailed analytics on SLNO stock on TipRanks’ Stock Analysis page.